GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » EBITDA Margin %

BLFS (BioLife Solutions) EBITDA Margin % : 2.79% (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioLife Solutions's EBITDA for the three months ended in Sep. 2024 was $0.9 Mil. BioLife Solutions's Revenue for the three months ended in Sep. 2024 was $30.6 Mil. Therefore, BioLife Solutions's EBITDA margin for the quarter that ended in Sep. 2024 was 2.79%.


BioLife Solutions EBITDA Margin % Historical Data

The historical data trend for BioLife Solutions's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions EBITDA Margin % Chart

BioLife Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.38 2.23 -14.92 -14.49 -31.58

BioLife Solutions Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.75 -43.30 -23.97 -15.61 2.79

Competitive Comparison of BioLife Solutions's EBITDA Margin %

For the Medical Instruments & Supplies subindustry, BioLife Solutions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's EBITDA Margin % falls into.



BioLife Solutions EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioLife Solutions's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-45.238/143.271
=-31.58 %

BioLife Solutions's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=0.853/30.571
=2.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions  (NAS:BLFS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


BioLife Solutions EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
Executives
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Greef Roderick De director
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023